Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment

Core Insights - Compass Therapeutics, Inc. (NASDAQ:CMPX) is recognized as one of the top multibagger stocks to consider for investment leading into 2026 [1] Analyst Coverage - Canaccord analyst John Newman initiated coverage of CMPX with a "Buy" rating and a $10 price target, citing positive data from second-line biliary tract cancer studies as a key factor [2] - Citizens JMP analyst Reni Benjamin also initiated coverage with an "Outperform" rating and a $10 price target, highlighting a 17% overall response rate for tovecimig in combination with paclitaxel in biliary tract cancers, compared to 5% in the paclitaxel-only arm [3] Clinical Progress - In the Q3 2025 update, management indicated that analyses of key secondary endpoints from the COMPANION-002 Phase 2/3 trial are expected to be reported in late Q1 2026 [4] - Preparations are underway for a Phase 2 basket study targeting multiple DLL4-positive tumors, alongside ongoing enrollment in a first-line combination trial [4] Company Overview - Compass Therapeutics is a clinical-stage oncology biopharmaceutical company focused on developing proprietary antibody-based therapies aimed at treating various cancers through mechanisms such as targeting angiogenesis and immune activation [5]